CurrentKaiser PermanentePolicy N/A

Neutron Beam Radiotherapy

Clinical review criteria for medical necessity determinations of neutron beam radiotherapy for Kaiser Permanente members in Washington; describes covered and not-covered indications and related authorization/code guidance.

Policy Summary

PayerKaiser Permanente

PolicyNeutron Beam Radiotherapy — Clinical Review Criteria (Radiation Oncology)

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateJun 12, 2002

Next Review DateN/A

Key ActionObtain pre-authorization for code 77423 and submit the last 6 months of clinical notes from the requesting provider and/or specialist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3indications

1covered codes

2002-06-12original date

multipleMTAC reviews

Coverage and Medical Necessity Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Experimental / investigational / not established indications

Not covered / experimental indications (Non-Medicare members):

Experimental/Investigational indications: Neutron beam therapy is considered experimental and investigational for all other indications because its effectiveness for these indications has not been established. Examples include, but are not limited to: colon cancer; dermatofibrosarcoma protuberans; glioma; kidney cancer; laryngeal cancer; lung cancer; pancreatic cancer; prostate cancer; rectal cancer; soft tissue sarcoma.

MTAC evidence conclusions (historical): Kaiser Permanente Medical Technology Assessment Committee (MTAC) reviews concluded that neutron beam radiotherapy did not meet MTAC criteria for some indications (historic reviews): soft tissue sarcoma; salivary gland tumors; locally advanced prostate cancer.

These are historical MTAC evidence conclusions cited in the policy development documents.

Kaiser Permanente considers the use of neutron beam therapy for indications other than the specified salivary gland tumor criteria to be experimental and investigational. Requests for neutron beam therapy for diagnoses beyond the covered salivary gland indications (for example, colon cancer, glioma, lung cancer, prostate cancer, soft tissue sarcoma, and others listed in the policy) have not established effectiveness and may be denied.

MTAC evidence reviews concluded that neutron beam radiotherapy does not meet Kaiser Permanente Medical Technology Assessment Criteria for several indications. For soft tissue sarcoma, available data were limited to case series with heterogeneous patients and inconsistent interventions, so efficacy could not be determined. For salivary gland tumors, one small randomized trial and multiple case series showed dramatic improvements in local/regional control favoring neutrons but carried methodological limitations and were considered insufficient for definitive conclusions. For locally advanced prostate cancer, two randomized trials reported improved local/regional control (and mixed findings for survival), but concerns about study quality, potential selection bias, and limited contemporary evidence led MTAC to determine the indication does not meet criteria.

Authorization, Documentation, and Denial Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for neutron beam therapy. Verify authorization for CPT code 77423 using the Pre-authorization Code Check to confirm plan-specific requirements before scheduling.

Affected code: 77423

Documentation Required

Request and include the last 6 months of clinical notes from the requesting provider and/or specialist with the pre-authorization submission to support medical necessity for salivary gland tumor indications.

Submit: Last 6 months of clinical notes from requesting provider/specialist

Denial Risk

Denial for Non‑Covered Indications

Neutron beam therapy is considered medically necessary only for salivary gland tumors that are inoperable, locally advanced (especially with gross residual disease), or unresectable. Requests not meeting these salivary gland tumor criteria are not covered and may be denied.

Denial applies when indication is not one of: inoperable tumor; locally advanced tumor (especially with gross residual disease); unresectable tumor
Examples of non-covered indications include (not all-inclusive): colon cancer, glioma, kidney cancer, laryngeal cancer, lung cancer, pancreatic cancer, prostate cancer, rectal cancer, soft tissue sarcoma, dermatofibrosarcoma protuberans

Note

Provider Next Steps

Providers should confirm authorization and submit required documentation (including the last 6 months of clinical notes) at time of request; use the Pre-authorization Code Check for plan-specific rules and CPT/code validation.

Confirm authorization for 77423
Include required documentation to avoid delays or denial

Background and Rationale

Neutron radiotherapy is a form of high linear-energy-transfer (high LET) radiation that produces denser ionization tracks than conventional photon (low LET) therapy. Because high LET radiation causes more severe DNA damage with less potential for cellular repair, neutron therapy may have greater biological effectiveness than photons, which can allow for lower total doses or fewer treatments in some settings. Historically, neutron therapy has been available at a limited number of specialized centers and has been most extensively studied for salivary gland tumors; however, the evidence base includes methodologic limitations and is not uniformly conclusive.

Definitions

High LET versus Low LET radiation

DefinitionNeutron radiotherapy is high linear-energy-transfer (LET) radiation; unlike photon (low LET) radiation, high LET causes damaged tumor cells to be much less likely to resume growth.

Biological effectivenessHigh LET (neutrons) has greater biological effectiveness than conventional photon therapy, allowing a required tumor dose of about one-third that needed with photons.

Repair of damaged cellsPhoton (low LET) radiation leaves a relatively high chance that damaged tumor cells can repair themselves; neutrons (high LET) produce less repair and less likelihood of tumor regrowth.

Clinical implicationsBecause neutrons are more biologically effective, they may require a lower total number of treatments and lower total physical dose compared with photon therapy.

Contrast summaryPhoton = low LET (greater cell repair, higher dose/fractionation typically required); Neutron = high LET (less cell repair, higher tumor kill per unit dose).

Policy Revision History

2002-06-12origin/creation

Policy originally created (Date Created 6/12/2002).

2020-10-06medicare guidance update

Removed unrelated SRS and SBRT LCD from Medicare, deferred to Kaiser Permanente criteria for Medicare (Date Reviewed 10/06/2020).

2020-10-06document review

Document reviewed (10/06/2020).

2021-10-05document review

Document reviewed (10/05/2021).

2022-10-04document review

Document reviewed (10/04/2022).

2023-10-03document review

Document reviewed (10/03/2023).

2024-04-02document review

Document reviewed (04/02/2024).

2025-04-01document review

Document reviewed (04/01/2025).

2026-04-07document reviewLatest

Document reviewed (04/07/2026).